Therapeutic Indications

Conferences & Courses
Protein & Antibody Engineering Protein & Antibody Engineering
March 31 - April 1, 2015 | Shanghai China
The field of protein engineering is at an exciting point in its development, with new generations of protein and antibody formats entering the market, improved understanding of structure-function relationships, and creative engineering that promises to op

Phage & Yeast Display Phage & Yeast Display
March 31 - April 1, 2015 | Shanghai China
Antibody generation, targeting membrane proteins, screening against challenging targets, generating novel constructs such as ADCs and bispecifics are all examples of today’s vast and important applications of screening and display technologies.

Antibody-Drug Conjugates Antibody-Drug Conjugates
April 1-2, 2015 | Shanghai China
Although there are currently only 2 ADCs on the market, there are nearly 100 companies active in the field.

Life Science Media Library
Understanding EMT: Mechanisms and Metastasis to MET Understanding EMT: Mechanisms and Metastasis to MET
February 20, 2012 |
Epethelial Mesenchymal Transition (EMT) plays a critical role in cancer cells, but understanding of its mechanisms is incomplete. EMT causes cells to develop increased motility, invasiveness, and greater resistance to apoptosis. These changes make the cells more like stem cells, allowing them to self renew. This course provides a framework of the underlying molecular mechanisms while addressing stem cells, and cancer progression, cMET and their activity as anti-metastasis agents, and the Mesenchymal-Epethelial Transition (MET) as an essential process for tumor re-initiation, colonization, and metastasis.
CTCs from Bench to Bed CTCs from Bench to Bed
February 20, 2012 |
This course will focus on validation of CTC research data for clinical practice, correlations between CTCs, diagnosis and responses to therapy.
Targeting Cancer Stem Cells Targeting Cancer Stem Cells
November 3, 2011 |
Cancer stem cells (CSCs) have been identified in several types of cancer, and may play a role in tumorigenic growth, metastasis, and therapeutic resistance. New anticancer therapeutics are being developed that will inhibit tumor growth and reduce tumor-initiating cell frequency, improving clinical cancer therapy. The development of new agents that block key CSC pathways will be described, as well as a novel assay for tracking CSCs in cell populations without the need to isolate them, and a CSC screening strategy for discovering therapeutic antibodies.

Publications, Reports, & Whitepapers
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Mgmt
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). This report also details the commercial aspects, market dynamics, and trends of liquid biopsy.
Vaccines: The End of Illness
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.